2260s5166
NM_001174063.1 NM_001174064.1 NM_001174065.1 NM_001174066.1 NM_001174067.1 NM_015850.3 NM_023105.2 NM_023106.2 NM_023110.2 XM_006716303.2 XM_006716304.1 XM_006716306.2 XM_006716307.1 XM_006716309.3 XM_006716310.2 XM_006716311.1 XM_006716312.1 XM_006716313.2 XM_006716314.1 XM_011544443.2 XM_011544444.1 XM_011544445.2 XM_011544446.2 XM_011544447.2 XM_011544448.1 XM_011544449.1 XM_011544450.2 XM_011544451.1 XM_011544452.2 XM_017013219.1 XM_017013220.1 XM_017013221.1 XM_017013222.1 XM_017013223.1 XM_017013224.1 XM_017013225.1 XM_017013226.1 XM_017013227.1 XM_017013228.1 XM_017013230.1 XM_017013231.1
10%(+/-2% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00241111_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.